Global Regenerative Medicine Market - Segment Analysis, Opportunity Assessment, Competitive Intelligence, Industry Outlook 2016-2026

Date : Apr 2020

|

Report ID : 232

|

Category : Healthcare

|
Report Format:  PDF EXCEL PPT WORD

Global Regenerative Medicine Market was valued at USD 13.56 billion in 2018 and is expected to reach USD 55.67 billion in 2026, growing at a CAGR of 19.4% during the forecast period.

Regenerative medicine therapies including advanced cell, gene, and tissue therapies—could help manage and potentially cure many conditions and diseases that are intractable, chronic, and even terminal. However, compared with more mature medical fields that feature a greater number of marketed products and a fully developed infrastructure (e.g., traditional pharmaceutical drugs, medical devices), the regenerative medicine field currently has few finalized standards, preventing many novel regenerative medicine therapies from becoming market-ready.

Regenerative Medicine Market Segmentation

                  By Type 1. Cell-Based Immunotherapy & Cell Therapy Products
2. Tissue-Engineered Products
3. Gene Therapy Products
 
                  By Application 1. Musculoskeletal Disorders
2. Wound Care
3. Oncology
4. Ocular Disorders
5. Diabetes
6. Others
 
                   By Region 1. North America (US and Canada)
2. Europe (UK, Germany, France and Rest of Europe)
3. Asia Pacific (China, Japan, India and Rest of Asia Pacific)
4. Latin America (Brazil, Mexico and Rest of Latin America)
5. Middle East & Africa (GCC and Rest of Middle East & Africa)
 


The growth of the regenerative medicine market is primarily driven by the increasing prevalence of the various chronic disease such as cancer, CVD and others across the globe. Major factors behind the burgeoning chronical conditions are the unhealthy lifestyle, alcohol consumption, smoking habits, and physical inactiveness. Cancer is the second leading cause mortalities in 2018, with continuous rise in the number of cancer patient across the globe, as per the report published by WHO. Furthermore, it is estimated that 1 out of 6 deaths occurs due to cancer every year across the globe. As per WHO, nearly one-third of the mortalities from cancer are due to 5 leading behavioural and dietary risk, which includes low fruit and vegetable intake, high body mass index, lack of physical activity, alcohol consumption, and tobacco use. Tobacco is one of the leading factors for the rise in the prevalence of cancer and mortalities that accounted for nearly 22% of the global population. The rising number of cancer patients is the major factor for the growth of global market. Moreover, technological advancement in the gene based products further provides growth opportunity to the market.

Global Regenerative Medicine Market Size, 2016-2026

Regenerative Medicine Market

The cell-based immunotherapy & cell therapy products segment expected to grow at the fastest rate of 23% CAGR during the forecast period

Based on type, the global regenerative medicine market has been segmented into cell-based immunotherapy & cell therapy products, tissue-engineered products, and gene therapy products. The cell-based immunotherapy & cell therapy products segment is projected to have the fastest market growth during the forecast period. Rising research and investment for the cell-based immunotherapies for the treatment of cancer is one of the key driving factors in segmental growth.

Based on application, the oncology segment is expected to lead during the forecast period

Based on indication, the market has been segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, diabetes, and others application. The oncology segment is projected to have largest share of 28% in the global market in 2018. The oncology segment is mainly driven due to increasing prevalence of cancer coupled with growing genomic research and government funding. The genomic profile platform enables to identify genes which are targeted by novel drugs. The drugs are developed with great sensitivity to target tumor cells. The genomic profiles enable in developing novel biomarkers which are used to diagnose disease, to predict patient and response to treatment.   

North America to dominate the regenerative medicine market throughout the forecast period

North America accounted for nearly 45% share of the global regenerative medicine market in 2018 and is expected to dominate the market throughout the forecast period followed by Europe and Asia-Pacific. Factors that are contributing significantly in the market growth include well-developed healthcare infrastructure, increasing healthcare R&D investments, high healthcare expenditure and so on. Moreover, the market growth is attributed to the rising prevalence of cancer and other chronic diseases. The rising number of cancer patients are considered to be one of the major factors that are driving the growth of market in the North American region. North America is one of the strongest economies globally, comprising of around 23.3% of the world economy as per International Monetary Fund in 2017. According to data from OECD, in 2016 the US spent almost 17.2% of GDP on the healthcare expenditure, whereas Canada spent 10.6% of GDP on healthcare. Asia-Pacific accounted for the highest CAGR in the global regenerative medicine market during the forecast period.

Company Profiles and Competitive Intelligence:

The major players operating in the global regenerative medicine market are Novartis International AG, (Switzerland), Vericel (US), Integra LifeSciences (US), Wright Medical (US), MiMedx (US), Osiris Therapeutics (US), Stryker Corporation (US), and Spark Therapeutics (US), Kite Pharma (US).

Need specific market information ?

Ask for free product review call with the author

Share your specific research requirements for a customized report

Request for due diligence and consumer centric studies

Request for study updates, segment specific and country level reports

TABLE OF CONTENT

Chapter 1 Executive Summary

1.1. Market Summary

1.1.1. Global Regenerative Medicine Market, 2016-2026, (USD Million)

1.2. Market Snapshot: Global Regenerative Medicine Market

1.3. Market Dynamics

1.4. Global Regenerative Medicine Market, by Segment, 2018

1.4.1. Global Regenerative Medicine Market, by Type, 2018, (USD Million)

1.4.2. Global Regenerative Medicine Market, by Application, 2018, (USD Million)

1.4.3. Global Regenerative Medicine Market, by Region, 2018 (USD Million)

1.5. Premium Insights

1.5.1. Regenerative Medicine Market in Developed Vs. Developing Economies, 2018 vs 2026

1.5.2. Global Regenerative Medicine Market: Regional Life Cycle Analysis

Chapter 2 Market Dynamics

2.1. Market Overview

2.2. Market Drivers

2.2.1. Increasing prevalence of chronic diseases and genetic diseases

2.2.2. Robust pipeline and product approval  

2.2.3. Growing government investments in regenerative medicine products

2.3. Market Restraints

2.3.1. Ethical Concerns Related to the Use of Embryonic Stem Cells in Research & Development

2.4. Market Opportunities

2.4.1. Rising Demand for Organ Transplantation

2.4.2. Implementation of the 21st Century Cures Act

2.5. Industry Value Chain Analysis

2.6. Pricing Analysis

2.7. Porter’s Five Forces Analysis

Chapter 3 Global Regenerative Medicine Market, by Type

3.1. Market Overview, by Type

3.1.1. Global Regenerative Medicine Market, by Type, 2016-2026 (USD Million)

3.1.2. Incremental Opportunity, by Type, 2018

3.2. Cell-Based Immunotherapy & Cell Therapy Products

3.2.1. Global Regenerative Medicine Market, by Cell-Based Immunotherapy & Cell Therapy Products, 2016-2026, (USD Million)

3.3. Tissue-Engineered Products

3.3.1. Global Regenerative Medicine Market, by Tissue-Engineered Products, 2016-2026, (USD Million)

3.4. Gene Therapy Products

3.4.1. Global Regenerative Medicine Market, by Gene Therapy Products, 2016-2026, (USD Million)

Chapter 4 Global Regenerative Medicine Market, by Application

4.1. Market Overview, by Application

4.1.1. Global Regenerative Medicine Market, by Application, 2016-2026 (USD Million)

4.1.2. Incremental Opportunity, by Application, 2018

4.2. Musculoskeletal Disorders

4.2.1. Global Regenerative Medicine Market, by Musculoskeletal Disorders, 2016-2026, (USD Million)

4.3. Wound Care

4.3.1. Global Regenerative Medicine Market, by Wound Care, 2016-2026, (USD Million)

4.4. Oncology

4.4.1. Global Regenerative Medicine Market, by Oncology, 2016-2026, (USD Million)

4.5. Ocular Disorders

4.5.1. Global Regenerative Medicine Market, by Ocular Disorders, 2016-2026, (USD Million)

4.6. Diabetes

4.6.1. Global Regenerative Medicine Market, by Diabetes, 2016-2026, (USD Million)

4.7. Others

4.7.1. Global Regenerative Medicine Market, by Others, 2016-2026, (USD Million)

Chapter 5 Global Regenerative Medicine Market, by Region

5.1. Market Overview, by Region

5.1.1. Global Regenerative Medicine Market, by Region, 2016-2026, (USD Million)

5.2. Attractive Investment Opportunity, by Region, 2018

5.3. North America Regenerative Medicine Market

5.3.1. North America Regenerative Medicine Market, by Type, 2016-2026 (USD Million)

5.3.2. North America Regenerative Medicine Market, by Application, 2016-2026 (USD Million)

5.3.3. United States Regenerative Medicine Market, 2016-2026 (USD Million)

5.3.4. Canada Regenerative Medicine Market, 2016-2026 (USD Million)

5.4. Europe Regenerative Medicine Market

5.4.1. Europe Regenerative Medicine Market, by Type, 2016-2026 (USD Million)

5.4.2. Europe Regenerative Medicine Market, by Application, 2016-2026 (USD Million)

5.4.3. United Kingdom Regenerative Medicine Market, 2016-2026 (USD Million)

5.4.4. Germany Regenerative Medicine Market, 2016-2026 (USD Million)

5.4.5. France Regenerative Medicine Market, 2016-2026 (USD Million)

5.4.6. Rest of Europe Regenerative Medicine Market, 2016-2026 (USD Million)

5.5. Asia Pacific Regenerative Medicine Market

5.5.1. Asia Pacific Regenerative Medicine Market, by Type, 2016-2026 (USD Million)

5.5.2. Asia Pacific Regenerative Medicine Market, by Application, 2016-2026 (USD Million)

5.5.3. China Regenerative Medicine Market, 2016-2026 (USD Million)

5.5.4. Japan Regenerative Medicine Market, 2016-2026 (USD Million)

5.5.5. India Regenerative Medicine Market, 2016-2026 (USD Million)

5.5.6. Rest of Asia Pacific Regenerative Medicine Market, 2016-2026 (USD Million)

5.6. Latin America Regenerative Medicine Market

5.6.1. Latin America Regenerative Medicine Market, by Type, 2016-2026 (USD Million)

5.6.2. Latin America Regenerative Medicine Market, by Application, 2016-2026 (USD Million)

5.6.3. Brazil Regenerative Medicine Market, 2016-2026 (USD Million)

5.6.4. Mexico Regenerative Medicine Market, 2016-2026 (USD Million)

5.6.5. Rest of Latin America Regenerative Medicine Market, 2016-2026 (USD Million)

5.7. Middle East & Africa Regenerative Medicine Market

5.7.1. Middle East & Africa Regenerative Medicine Market, by Type, 2016-2026 (USD Million)

5.7.2. Middle East & Africa Regenerative Medicine Market, by Application, 2016-2026 (USD Million)

5.7.3. GCC Regenerative Medicine Market, 2016-2026 (USD Million)

5.7.4. Rest of Middle East & Africa Regenerative Medicine Market, 2016-2026 (USD Million)

Chapter 6 Competitive Intelligence

6.1. Top 5 Players Comparison

6.2. Market Positioning of Key Players, 2018

6.3. Market Players Mapping

6.3.1. By Type

6.3.2. By Application

6.3.3. By Region

6.4. Strategies Adopted by Key Market Players

6.5. Recent Developments in the Market

6.5.1. Mergers & Acquisitions, Partnership, New Product Developments

Chapter 7 Company Profiles

7.1. Novartis International AG

7.1.1. Novartis International AG Overview

7.1.2. Novartis International AG Products Portfolio

7.1.3. Novartis International AG Financial Overview

7.1.4. Novartis International AG News/Recent Developments

7.2. Vericel

7.2.1. Vericel Overview

7.2.2. Vericel Products Portfolio

7.2.3. Vericel Financial Overview

7.2.4. Vericel News/Recent Developments

7.3. Integra Lifesciences

7.3.1. Integra Lifesciences Overview

7.3.2. Integra Lifesciences Products Portfolio

7.3.3. Integra Lifesciences Financial Overview

7.3.4. Integra Lifesciences News/Recent Developments

7.4. Mimedx Group

7.4.1. Mimedx Group Overview

7.4.2. Mimedx Group Products Portfolio

7.4.3. Mimedx Group Financial Overview

7.4.4. Mimedx Group News/Recent Developments

7.5. Stryker Corp.

7.5.1. Stryker Corp. Overview

7.5.2. Stryker Corp. Products Portfolio

7.5.3. Stryker Corp. Financial Overview

7.5.4. Stryker Corp. News/Recent Developments

7.6. Wright Medical

7.6.1. Wright Medical Overview

7.6.2. Wright Medical Products Portfolio

7.6.3. Wright Medical Financial Overview

7.6.4. Wright Medical News/Recent Developments

7.7. Spark Therapeutics

7.7.1. Spark Therapeutics Overview

7.7.2. Spark Therapeutics Products Portfolio

7.7.3. Spark Therapeutics Financial Overview

7.7.4. Spark Therapeutics News/Recent Developments

7.8. Osiris Therapeutics

7.8.1. Osiris Therapeutics Overview

7.8.2. Osiris Therapeutics Products Portfolio

7.8.3. Osiris Therapeutics Financial Overview

7.8.4. Osiris Therapeutics News/Recent Developments

7.9. Kite Pharma

7.9.1. Kite Pharma Overview

7.9.2. Kite Pharma Products Portfolio

7.9.3. Kite Pharma Financial Overview

7.9.4. Kite Pharma News/Recent Developments

7.10. Organogenesis

7.10.1. Organogenesis Overview

7.10.2. Organogenesis Products Portfolio

7.10.3. Organogenesis Financial Overview

7.10.4. Organogenesis News/Recent Developments

Chapter 8 Preface

8.1. Data Triangulation

8.2. Research Methodology

8.2.1. Application I – Secondary Research

8.2.2. Application II – Primary Research

8.2.3. Application III – Expert Panel Review

8.2.4. Approach Adopted

8.2.4.1. Top-Down Approach

8.2.4.2. Bottom-Up Approach

8.2.5. Supply- Demand side

8.2.6. Breakup of the Primary Profiles


Choose License

Buy Now

Why Choose AllTheResearch?

  • Monthly market updates for 6 months
  • Online access of reports
  • Options to buy sections of report
  • Critically analysed research on “Quadrant Positioning” of your company.
  • Syndicated report along with a supplementary report with objective-based study
  • Get profiled in the reports. Expanding your visibility across our network of readers and viewers
  • We provide local market data in local language on request
  • A complementary co-branded white paper
  • Flat consulting fee based exclusive studies. Consult at the price of syndicate
  • Access to expert team for free transaction advisory service.


Quick Inquiry

Follow Us